Karyopharm Therapeutics Inc.骨髓纤维化III期Sentry试验顶线数据预计2026年3月发布

美股速递
Oct 08, 2025

Karyopharm Therapeutics Inc.宣布,其针对骨髓纤维化适应症的III期Sentry临床试验进展顺利,顶线数据预计将于2026年3月按计划公布。

该项关键性试验旨在评估公司核心药物在治疗骨髓纤维化患者中的疗效和安全性。骨髓纤维化是一种罕见的血液肿瘤疾病,目前治疗选择有限,患者迫切需要新的治疗方案。

试验数据的如期发布将为公司后续的监管申请和商业化进程奠定重要基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10